Mobile website
Therapeutic Effects of Tumor Antigen-Pulsed, IL-2 Gene-Modified Dendritic Cells Combined with Low-Dose Cyclophosphamide on Matastatic Lung Carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the antitumor effects and the possible mechanisms of tumor antigen peptide-pulsed, IL-2 gene-modified dendritic cells (DCs) in combination with low-dose cyclophosphamide (Cy). Methods: Mutl is a MHC class I -restricted tumor antigen peptide of 3LL Lewis lung carcinoma. The mice bearing metastatic lung carcinoma were treated by vaccination with DCs transfected with IL-2 gene and pulsed with Mutl, then the survival period of mice were observed. The phenotypes of splenocytes were detected by FACS and the cytotoxicity of CTL and NK were assayed by 4h-51Cr release assay. Results: The combind treatment could inhibit pulmonary metastasis of tumor most significantly and increase the proportion of the CD8 T cells, NK1.1 cells in spleen mononuclear cells. The highest CTL cytotoxicity could be induced. Conclusion: Tumor antigen peptide-pulsed,IL-2 gene-modified DCs combined with low-dose Cy could induce antitumor immune response most potently and then inhibit tumor pulmonary metastasis most significantly.
Keywords:
Project Supported:
Clc Number:
R730.5
